Publications by authors named "Fenghao Shi"

Claim this Profile
C
Cost-effectiveness analysis of the combination of low-dose nivolumab with triple metronomic chemotherapy for advanced head and neck squamous cell carcinoma in China.
Yingdan Cao, Fenghao Shi, Xiaoxia Wei, Sheng Han, Yu Fang

Front Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of CDK4/6 inhibitors for second-line HR+/HER2- advanced or metastatic breast cancer in China.
Caifeng Jia, Sen Zhang, Jie Wang, Bing Feng, Fenghao Shi

Sci Rep· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of universal genetic screening for familial hypercholesterolemia in young adults aged 18-40 years in China.
Rui Meng, Fenghao Shi, Baoming Zhang, Chao Li, Jinyan Wang

BMC Med· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of amivantamab plus chemotherapy for non-small cell lung cancer patients with epidermal growth factor receptor exon 20 insertions in the United States.
Yingdan Cao, Hongbin Yi, Fenghao Shi, Xiaoxia Wei, Sheng Han

Int J Clin Pharm· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of selpercatinib versus chemotherapy and pembrolizumab in the first-line treatment of rearranged during transfection fusion-positive non-small cell lung cancer in the United States.
Hongbin Yi, Yingdan Cao, Fenghao Shi, Xiaoxia Wei, Sheng Han

Int J Clin Pharm· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of atezolizumab plus bevacizumab and chemotherapy for the treatment of metastatic, persistent, or recurrent cervical cancer (BEATcc).
Yixiao Zhu, Fenghao Shi, Huiting Lin, Yingdan Cao, Hongbin Yi

Expert Rev Pharmacoecon Outcomes Res· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of immune checkpoint inhibitors as first-line therapy in advanced biliary tract cancer.
Ruizhe Liu, Yijia Zhao, Fenghao Shi, Jianhong Zhu, Junyan Wu

Immunotherapy· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of PD-1 inhibitors as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma in China: an economic evaluation based on network meta-analysis.
Shuang Liu, Linbo Zhao, Fenghao Shi, Liping Kuai, Ruizhe Liu

Int J Clin Pharm· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of durvalumab plus tremelimumab in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer from the US healthcare sector's and societal perspectives.
Yena Gan, Fenghao Shi, He Zhu, Huangqianyu Li, Sheng Han

Front Pharmacol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impacts of adjustment of National Reimbursement Drug List on orphan drugs volume and spending in China: an interrupted time series analysis.
Hongbin Yi, Fenghao Shi, Zihao Wang, Liping Kuai, Dongyan Xu

BMJ Open· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adebrelimab plus chemotherapy vs. chemotherapy for treatment of extensive-stage small-cell lung cancer from the US and Chinese healthcare sector perspectives: a cost-effectiveness analysis to inform drug pricing.
Yena Gan, Fenghao Shi, He Zhu, Sheng Han, Duoduo Li

Front Pharmacol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line treatments for advanced hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis in China and the United States.
Ke-Xin Sun, Shan-Shan Cao, Feng-Hao Shi, Yue Guan, Meng Tang

Therap Adv Gastroenterol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic evaluation of tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.
Fenghao Shi, Zixuan He, Hang Su, Lin Wang, Sheng Han

Front Pharmacol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of edaravone dexborneol versus edaravone for the treatment of acute ischemic stroke in China: Based on the TASTE study.
Fenghao Shi, Zixuan He, Lin Wang, Hang Su, Sheng Han

Front Pharmacol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Systematic Review of Methods and Study Quality of Economic Evaluations for the Treatment of Schizophrenia.
Luying Wang, Fenghao Shi, Xin Guan, He Xu, Jing Liu

Front Public Health· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Will the Inducing and Maintaining Remission of Non-biological Agents and Biological Agents Differ for Crohn's Disease? The Evidence From the Network Meta-Analysis.
Mingjun Rui, Zhengyang Fei, Yingcheng Wang, Fenghao Shi, Rui Meng

Front Med (Lausanne)· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model.
Mingjun Rui, Fenghao Shi, Ye Shang, Rui Meng, Hongchao Li

Adv Ther· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis